Centessa Pharmaceuticals Plc Financials

CNTA

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Neutral

4/9

Centessa Pharmaceuticals Plc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.60x

For every $1 of reported earnings, Centessa Pharmaceuticals Plc generates $0.60 in operating cash flow (-$142.1M OCF vs -$235.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-19.9x

Centessa Pharmaceuticals Plc earns $-19.9 in operating income for every $1 of interest expense (-$201.1M vs $10.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Centessa Pharmaceuticals Plc (CNTA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

YoY-100.0%

Centessa Pharmaceuticals Plc generated $0 in revenue in fiscal year 2024. This represents a decrease of 100.0% from the prior year.

EBITDA

-$200.1M

YoY-17.4%

Centessa Pharmaceuticals Plc's EBITDA was -$200.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 17.4% from the prior year.

Free Cash Flow

-$142.1M

YoY+11.5%

Centessa Pharmaceuticals Plc generated -$142.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 11.5% from the prior year.

Net Income

-$235.8M

YoY-56.0%

Centessa Pharmaceuticals Plc reported -$235.8M in net income in fiscal year 2024. This represents a decrease of 56.0% from the prior year.

EPS (Diluted)

$-2.06

YoY-31.2%

Centessa Pharmaceuticals Plc earned $-2.06 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 31.2% from the prior year.

Cash & Debt

$383.2M

YoY+199.3%

5Y CAGR+87.4%

Centessa Pharmaceuticals Plc held $383.2M in cash against $108.9M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

133M

YoY+34.3%

Centessa Pharmaceuticals Plc had 133M shares outstanding in fiscal year 2024. This represents an increase of 34.3% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$150.2M

YoY+20.8%

5Y CAGR+103.9%

Centessa Pharmaceuticals Plc invested $150.2M in research and development in fiscal year 2024. This represents an increase of 20.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$34K

YoY-79.9%

Centessa Pharmaceuticals Plc invested $34K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 79.9% from the prior year.

CNTA Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$0-100.0%	$6.9M	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$150.2M+20.8%	$124.4M-19.8%	$155.1M+62.1%	$95.7M+928.5%	$9.3M+118.2%	$4.3M
SG&A Expenses	$50.8M-5.4%	$53.7M-2.7%	$55.2M+28.7%	$42.9M+3665.4%	$1.1M+44.2%	$790K
Operating Income	-$201.1M-17.4%	-$171.3M+19.3%	-$212.3M+43.3%	-$374.1M-3483.2%	-$10.4M-106.6%	-$5.1M
Interest Expense	$10.1M+1.9%	$9.9M+36.1%	$7.3M	N/A	N/A	N/A
Income Tax	$2.8M+111.4%	-$25.1M-3254.2%	-$747K-755.3%	$114K	$0	$0
Net Income	-$235.8M-56.0%	-$151.1M+30.1%	-$216.2M+43.3%	-$381.1M-3473.8%	-$10.7M-110.7%	-$5.1M
EPS (Diluted)	$-2.06-31.2%	$-1.57+32.0%	$-2.31+54.4%	$-5.07	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$0	$0-100.0%	$15.0M	$0	$0	$0	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$41.6M-2.8%	$42.7M+27.8%	$33.4M-45.1%	$60.9M+85.5%	$32.8M+44.9%	$22.7M	N/A	$28.2M
SG&A Expenses	$12.2M+2.6%	$11.9M-3.4%	$12.3M-10.0%	$13.7M+22.8%	$11.2M-16.9%	$13.4M	N/A	$12.0M
Operating Income	-$53.8M+1.6%	-$54.7M-77.6%	-$30.8M+58.7%	-$74.6M-69.6%	-$44.0M-21.9%	-$36.1M	N/A	-$40.2M
Interest Expense	$2.9M+0.2%	$2.9M+0.2%	$2.9M+16.1%	$2.5M-1.8%	$2.5M-0.2%	$2.5M	N/A	$2.5M
Income Tax	$166K-78.7%	$778K-44.3%	$1.4M+33.0%	$1.1M+48.9%	$705K+46.6%	$481K	N/A	-$2.8M
Net Income	-$54.9M-9.0%	-$50.3M-92.6%	-$26.1M+76.5%	-$111.3M-154.1%	-$43.8M-15.2%	-$38.0M	N/A	-$38.6M
EPS (Diluted)	$-0.41-7.9%	$-0.38-90.0%	$-0.20+78.0%	$-0.91-127.5%	$-0.40-5.3%	$-0.38	N/A	$-0.40

CNTA Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$576.8M+60.1%	$360.2M-18.9%	$444.3M-29.4%	$629.6M+5273.7%	$11.7M	N/A
Current Assets	$536.4M+70.2%	$315.1M-28.0%	$437.7M-30.4%	$628.8M+5531.7%	$11.2M	N/A
Cash & Equivalents	$383.2M+199.3%	$128.0M-67.5%	$393.6M-33.9%	$595.1M+8134.1%	$7.2M-56.4%	$16.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$175.3M+41.3%	$124.0M+14.7%	$108.1M-21.7%	$138.1M+743.6%	$16.4M	N/A
Current Liabilities	$58.0M+47.3%	$39.4M+2.7%	$38.3M+55.6%	$24.6M+185.9%	$8.6M	N/A
Long-Term Debt	$108.9M+43.9%	$75.7M+8.5%	$69.8M-7.8%	$75.7M	$0	N/A
Total Equity	$401.5M+70.0%	$236.2M-29.7%	$336.2M-31.6%	$491.6M+10668.8%	-$4.7M	N/A
Retained Earnings	-$988.7M-31.3%	-$752.9M-25.1%	-$601.9M-56.1%	-$385.7M	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$448.3M-8.9%	$492.1M-6.8%	$527.8M-8.5%	$576.8M+44.6%	$398.8M+21.5%	$328.2M-8.9%	$360.2M-4.5%	$377.4M
Current Assets	$307.7M+2.4%	$300.4M-13.6%	$347.7M-35.2%	$536.4M+50.9%	$355.5M+25.0%	$284.5M-9.7%	$315.1M-5.2%	$332.5M
Cash & Equivalents	$50.8M+14.8%	$44.2M-57.9%	$105.2M-72.6%	$383.2M+200.9%	$127.4M+7.7%	$118.2M-7.7%	$128.0M-25.3%	$171.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$146.7M-0.3%	$147.2M+4.0%	$141.6M-19.2%	$175.3M+56.6%	$111.9M-1.0%	$113.0M-8.9%	$124.0M+5.1%	$118.0M
Current Liabilities	$29.1M-1.9%	$29.7M+22.7%	$24.2M-58.3%	$58.0M+116.8%	$26.8M-2.5%	$27.4M-30.3%	$39.4M+12.7%	$35.0M
Long-Term Debt	$109.8M+0.2%	$109.5M+0.3%	$109.3M+0.3%	$108.9M+42.4%	$76.5M-0.4%	$76.8M+1.5%	$75.7M+2.3%	$74.0M
Total Equity	$301.6M-12.6%	$344.9M-10.7%	$386.2M-3.8%	$401.5M+39.9%	$287.0M+33.4%	$215.2M-8.9%	$236.2M-8.9%	$259.4M
Retained Earnings	-$1.1B-5.2%	-$1.1B-5.0%	-$1.0B-2.6%	-$988.7M-18.4%	-$834.8M-5.5%	-$791.0M-5.1%	-$752.9M-5.1%	-$716.1M

CNTA Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$142.1M+11.4%	-$160.3M+20.0%	-$200.5M-48.4%	-$135.1M-1171.0%	-$10.6M-82.5%	-$5.8M
Capital Expenditures	$34K-79.9%	$169K-85.1%	$1.1M+511.3%	$186K	$0	$0
Free Cash Flow	-$142.1M+11.5%	-$160.5M+20.4%	-$201.7M-49.1%	-$135.3M-1172.8%	-$10.6M-82.5%	-$5.8M
Investing Cash Flow	$31.3M+124.6%	-$127.0M-13541.7%	-$931K-101.5%	$63.3M	$0	$0
Financing Cash Flow	$364.8M+1627.3%	$21.1M+4520.8%	$457K-99.9%	$660.1M+48368.9%	$1.4M-84.9%	$9.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$12K	$0	$0

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$58.3M-159.7%	-$22.5M+60.8%	-$57.2M-33.8%	-$42.8M-5.5%	-$40.6M-8.8%	-$37.3M-20.1%	-$31.1M+17.0%	-$37.4M
Capital Expenditures	$234K	N/A	N/A	$0	$0	$0-100.0%	$28K-34.9%	$43K
Free Cash Flow	-$58.5M	N/A	N/A	-$42.8M-5.5%	-$40.6M-8.8%	-$37.3M-20.0%	-$31.1M+17.0%	-$37.4M
Investing Cash Flow	$61.9M+255.0%	-$40.0M+82.0%	-$222.4M-989.6%	$25.0M+145.1%	-$55.5M-430.9%	$16.8M+191.7%	-$18.3M-137.5%	$48.7M
Financing Cash Flow	$3.4M+114.1%	$1.6M-48.0%	$3.1M+4.2%	$3.0M-97.2%	$105.3M+903.7%	$10.5M+65.0%	$6.4M-56.9%	$14.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CNTA Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-2499.4%	N/A	N/A	N/A	N/A
Net Margin	N/A	-2204.7%	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-40.9%+1.1pp	-41.9%+6.7pp	-48.7%+11.9pp	-60.5%+30.5pp	-91.0%	N/A
Current Ratio	9.25+1.2	8.00-3.4	11.42-14.1	25.52+24.2	1.30	N/A
Debt-to-Equity	0.27-0.0	0.32+0.1	0.21+0.1	0.15+0.2	0.00	N/A
FCF Margin	N/A	-2342.2%	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-205.2%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	-174.2%	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-12.2%-2.0pp	-10.2%-5.3pp	-5.0%+14.4pp	-19.3%-8.3pp	-11.0%+0.6pp	-11.6%	N/A	-10.2%
Current Ratio	10.56+0.4	10.12-4.3	14.37+5.1	9.25-4.0	13.29+2.9	10.37+2.4	8.00-1.5	9.51
Debt-to-Equity	0.36+0.0	0.32+0.0	0.28+0.0	0.270.0	0.27-0.1	0.36+0.0	0.32+0.0	0.29
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Crinetics Pharmaceuticals CRNX

$4.4B

Telix Pharmaceuticals Ltd ADR TLX

$2.2B

Scholar Rock Holding SRRK

$4.7B

Immunovant Inc IMVT

$5.2B

Viking Therapeutics Inc VKTX

$3.4B

Frequently Asked Questions

What is Centessa Pharmaceuticals Plc's annual revenue?

Centessa Pharmaceuticals Plc (CNTA) reported $0 in total revenue for fiscal year 2024. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Centessa Pharmaceuticals Plc's revenue growing?

Centessa Pharmaceuticals Plc (CNTA) revenue declined by 100% year-over-year, from $6.9M to $0 in fiscal year 2024.

Is Centessa Pharmaceuticals Plc profitable?

No, Centessa Pharmaceuticals Plc (CNTA) reported a net income of -$235.8M in fiscal year 2024.

What is Centessa Pharmaceuticals Plc's earnings per share (EPS)?

Centessa Pharmaceuticals Plc (CNTA) reported diluted earnings per share of $-2.06 for fiscal year 2024. This represents a -31.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Centessa Pharmaceuticals Plc's EBITDA?

Centessa Pharmaceuticals Plc (CNTA) had EBITDA of -$200.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Centessa Pharmaceuticals Plc have?

As of fiscal year 2024, Centessa Pharmaceuticals Plc (CNTA) had $383.2M in cash and equivalents against $108.9M in long-term debt.

What is Centessa Pharmaceuticals Plc's free cash flow?

Centessa Pharmaceuticals Plc (CNTA) generated -$142.1M in free cash flow during fiscal year 2024. This represents a 11.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Centessa Pharmaceuticals Plc's operating cash flow?

Centessa Pharmaceuticals Plc (CNTA) generated -$142.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Centessa Pharmaceuticals Plc's total assets?

Centessa Pharmaceuticals Plc (CNTA) had $576.8M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Centessa Pharmaceuticals Plc's capital expenditures?

Centessa Pharmaceuticals Plc (CNTA) invested $34K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Centessa Pharmaceuticals Plc spend on research and development?

Centessa Pharmaceuticals Plc (CNTA) invested $150.2M in research and development during fiscal year 2024.

How many shares does Centessa Pharmaceuticals Plc have outstanding?

Centessa Pharmaceuticals Plc (CNTA) had 133M shares outstanding as of fiscal year 2024.

What is Centessa Pharmaceuticals Plc's current ratio?

Centessa Pharmaceuticals Plc (CNTA) had a current ratio of 9.25 as of fiscal year 2024, which is generally considered healthy.

What is Centessa Pharmaceuticals Plc's debt-to-equity ratio?

Centessa Pharmaceuticals Plc (CNTA) had a debt-to-equity ratio of 0.27 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Centessa Pharmaceuticals Plc's return on assets (ROA)?

Centessa Pharmaceuticals Plc (CNTA) had a return on assets of -40.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Centessa Pharmaceuticals Plc's cash runway?

Based on fiscal year 2024 data, Centessa Pharmaceuticals Plc (CNTA) had $383.2M in cash against an annual operating cash burn of $142.1M. This gives an estimated cash runway of approximately 32 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Centessa Pharmaceuticals Plc's Piotroski F-Score?

Centessa Pharmaceuticals Plc (CNTA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Centessa Pharmaceuticals Plc's earnings high quality?

Centessa Pharmaceuticals Plc (CNTA) has an earnings quality ratio of 0.60x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Centessa Pharmaceuticals Plc cover its interest payments?

Centessa Pharmaceuticals Plc (CNTA) has an interest coverage ratio of -19.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.